Copley-Merriman Catherine, Yang Xiaoqin, Juniper Melissa, Amin Suvina, Yoo Hyun Kyoo, Sen Shuvayu S
RTI Health Solutions, Research Triangle Park, NC, USA.
Merck & Co., Inc., Kenilworth, NJ, USA.
Adolesc Health Med Ther. 2021 May 19;12:55-66. doi: 10.2147/AHMT.S303456. eCollection 2021.
Neurofibromatosis type 1 (NF1) is an incurable genetic condition that frequently includes the development of plexiform neurofibromas (PNs) in patients. A systematic literature review was conducted to identify data on the natural history, disease burden, and treatment patterns among patients diagnosed with NF1 and PN, as well as to identify evidence gaps in these areas. MEDLINE and MEDLINE In-Process, Embase, and Cochrane Library Searches were searched using predefined terms. Potential references underwent two phases of screening by two independent researchers. A total of 39 references focusing on populations of patients with both NF1 and PN were included in this review. The wide range of PN-related complications creates a substantial quality-of-life (QOL) burden for patients, including pain, social functioning, physical function impact, stigma, and emotional distress. The severe burden of NF1 with PN on the QOL of patients demonstrates the high unmet need for an effective treatment option that can reduce tumor burden and improve QOL. The heterogeneity of measurement tools used to evaluate QOL and the gap in data evaluating the health economic burden of PN should be the focus of future research.
1型神经纤维瘤病(NF1)是一种无法治愈的遗传性疾病,患者常出现丛状神经纤维瘤(PNs)。本研究进行了一项系统的文献综述,以确定诊断为NF1和PN的患者的自然病史、疾病负担和治疗模式的数据,并找出这些领域的证据空白。使用预定义术语检索了MEDLINE、MEDLINE在研数据库、Embase和Cochrane图书馆数据库。两位独立研究人员对潜在参考文献进行了两个阶段的筛选。本综述共纳入了39篇关注NF1和PN患者群体的参考文献。广泛的PN相关并发症给患者带来了巨大的生活质量(QOL)负担,包括疼痛、社交功能、身体功能影响、耻辱感和情绪困扰。NF1合并PN对患者QOL的严重负担表明,对于能够减轻肿瘤负担并改善QOL的有效治疗方案存在高度未满足的需求。用于评估QOL的测量工具的异质性以及评估PN健康经济负担的数据缺口应成为未来研究的重点。